Outcomes with simultaneous administration of all-transretinoic acid (ATRA) plus chemotherapy-based regimens in patients with newly diagnosed acute promyelocytic leukemia (APL).
| Cooperative group, Reference . | Induction Regimen . | n . | Non-Eligiblen(%) . | Median age (Range) . | CRn(%) . | DFX % . | CIR % . | OS % . |
|---|---|---|---|---|---|---|---|---|
| * Patients aged < 65 years with WBC < 5 ×109/L | ||||||||
| ** Patients with WBC > 5 ×109/L | ||||||||
| † Patients aged > 65 years with WBC < 5 ×109/L | ||||||||
| ‡ extended ATRA arm; | ||||||||
| § Risk-adapted consolidation with ATRA for intermediate and high-risk patients. | ||||||||
| Abbreviations: CR, complete remission; DFX, desferrioxamine; CIR, cumulative incidence of relapse; OS, overall survival | ||||||||
| GIMEMA Mandelli et al (1997) | ATRA + Idarubicin | 253 | 21 (8) | 38 (2–74) | 229 (95) | 79 (2y) | NA | 87 (2y) |
| European APL | ATRA + Daunorubicin | 99* | NA | 43 (7–63) | NA (94) | NA | 11 (2y) | 84 (2y) |
| Fenaux et al (1999) | + Cytarabine | 163** | NA | 42 (1–73) | NA (90) | NA | 29 (2y) | 77 (2y) |
| 42 † | NA | 69 (65–77) | NA (90) | NA | 7 (2y) | 69 (2y) | ||
| MRC Burnett et al (2000) | ATRA + Anthracycline + Cytarabine +/− Etoposide | 120 ‡ | NA | NA | NA (87) | 72 (4y) | 20 (4y) | 71 (4y) |
| GAMLCG Lengfelder et al (2000) | ATRA + Daunorubicin + Cytarabine + Thioguanine | 51 | 11 (18) | 43 (16–60) | 47 (92) | 96 (2y) | NA | 88 (2y) |
| PETHEMA Sanz et al (1999) | ATRA + Idarubicin | 123 | 13 (10) | 42 (1–74) | 109 (89) | 92 (2y) | NA | 82 (2y) |
| PETHEMA Sanz et al (2004) | ATRA + Idarubicin§ | 251 | 28 (10) | 39 (2–81) | 227 (90) | 90 (3y) | 7.5 (3y) | 85 (3y) |
| Cooperative group, Reference . | Induction Regimen . | n . | Non-Eligiblen(%) . | Median age (Range) . | CRn(%) . | DFX % . | CIR % . | OS % . |
|---|---|---|---|---|---|---|---|---|
| * Patients aged < 65 years with WBC < 5 ×109/L | ||||||||
| ** Patients with WBC > 5 ×109/L | ||||||||
| † Patients aged > 65 years with WBC < 5 ×109/L | ||||||||
| ‡ extended ATRA arm; | ||||||||
| § Risk-adapted consolidation with ATRA for intermediate and high-risk patients. | ||||||||
| Abbreviations: CR, complete remission; DFX, desferrioxamine; CIR, cumulative incidence of relapse; OS, overall survival | ||||||||
| GIMEMA Mandelli et al (1997) | ATRA + Idarubicin | 253 | 21 (8) | 38 (2–74) | 229 (95) | 79 (2y) | NA | 87 (2y) |
| European APL | ATRA + Daunorubicin | 99* | NA | 43 (7–63) | NA (94) | NA | 11 (2y) | 84 (2y) |
| Fenaux et al (1999) | + Cytarabine | 163** | NA | 42 (1–73) | NA (90) | NA | 29 (2y) | 77 (2y) |
| 42 † | NA | 69 (65–77) | NA (90) | NA | 7 (2y) | 69 (2y) | ||
| MRC Burnett et al (2000) | ATRA + Anthracycline + Cytarabine +/− Etoposide | 120 ‡ | NA | NA | NA (87) | 72 (4y) | 20 (4y) | 71 (4y) |
| GAMLCG Lengfelder et al (2000) | ATRA + Daunorubicin + Cytarabine + Thioguanine | 51 | 11 (18) | 43 (16–60) | 47 (92) | 96 (2y) | NA | 88 (2y) |
| PETHEMA Sanz et al (1999) | ATRA + Idarubicin | 123 | 13 (10) | 42 (1–74) | 109 (89) | 92 (2y) | NA | 82 (2y) |
| PETHEMA Sanz et al (2004) | ATRA + Idarubicin§ | 251 | 28 (10) | 39 (2–81) | 227 (90) | 90 (3y) | 7.5 (3y) | 85 (3y) |